GFOR News and Press, Graf Acquisition Corp. IV From 04/17/23

2023-04-17 02:23:12 ET Clinical stage natural killer cell therapy company, NKGen Biotech enters merger with Graf Acquisition ( NYSE: GFOR ). NKGen is expected to have a pro forma enterprise value of at least $160M, based on $145M in pre-money equity value plus conversion to ...

NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.’s non-genetically modified, enhanced and expanded NK cells have the potential to be a possi...

2023-03-24 15:17:15 ET SPAC Graf Acquisition Corp. IV ( NYSE: GFOR ) has signed a non-binding letter of intent to merge with immunotherapy developer NKGen Biotech. Graf IV said it would release more details about the deal when a definitive agreement is reached. Based in ...

Graf Acquisition Corp. IV (NYSE: GFOR) (“Graf”), a NYSE-listed special purpose acquisition company founded by serial SPAC founder James Graf, and NKGen Biotech, Inc. (“NKGen Biotech”), a biotechnology company focused on harnessing the power of the body’s immune ...

Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the “Company”) today announced that it is withdrawing from the ballot for its special meeting of stockholders to be held on December 21, 2022 (the “Special Meeting”) the proposal to amend the Company’s cer...

GSR II Meteora Acquisition went public recently, raising around $316 million in an IPO. The SPAC seeks to merge with a company in one of a wide variety of industry sectors. While management has extensive SPAC industry expertise, its limited track record has not delivered investor ...